$CRBP (CORBUS PHARMACEUTICALS HOLDI..) — 8-K: Corbus CRB-913 Hits 5% Weight Loss at 12 Weeks in Phase 1b Obesity Trial

In the CANYON-1 Phase 1b trial of 254 obese, non-diabetic adults, CRB-913 produced placebo-adjusted mean weight loss of 2.8% at 20 mg, 3.3% at 40 mg, and 5.0% at 60 mg after 12 weeks, with no plateau observed at any dose. The 60 mg cohort achieved 5.0% mean weight loss versus 0.0% for placebo. CRB-913 was generally well tolerated, with psychiatric adverse events broadly in line with GLP-1 drugs and fewer gastrointestinal adverse events versus published data for marketed oral GLP-1 drugs. Data support a Phase 2 study and were selected for a late-breaking presentation at ObesityWeek 2026.

In the CANYON-1 Phase 1b trial of 254 obese, non-diabetic adults, CRB-913 produced placebo-adjusted mean weight loss of 2.8% at 20 mg, 3.3% at 40 mg, and 5.0% at 60 mg after 12 weeks, with no plateau